Dvatse Long effervescent tablets 600 mg tube 10 pcs.

Active ingredient: acetylcysteine.

1 effervescent tablet contains 600 mg of acetylcysteine.

Excipients: maltodextrin, anhydrous citric acid, sodium bicarbonate, orange flavoring, leucine, sodium saccharin.

Hypersensitivity to acetylcysteine ​​or to other components of the drug. Gastric and duodenal ulcer in the acute stage, hemoptysis, pulmonary hemorrhage, severe exacerbation of bronchial asthma.

Adults and children aged 12 and over

Dissolve 600 mg effervescent tablets in 1/3 cup of water and take once a day.

Additional fluid intake enhances the mucolytic effect of the drug.

The duration of the course of treatment is determined by the doctor individually, depending on the nature of the disease (acute or chronic). The drug should not be taken for more than 4–5 days without consulting a doctor.

Patients with bronchial asthma should be closely monitored during treatment due to the possible development of bronchospasm. In the event of bronchospasm, treatment with acetylcysteine ​​should be discontinued immediately.

There are isolated reports of severe skin reactions (Stevens-Johnson and Lyell syndromes) when taking acetylcysteine, therefore, in the event of changes in the skin or mucous membranes, the use of the drug should be immediately discontinued and a doctor should be consulted regarding its further use.

It is recommended to use the drug with caution in patients with a history of gastric and duodenal ulcers, especially in case of concomitant use of other drugs that irritate the gastric mucosa.

Acetylcysteine ​​should be prescribed with caution to patients with liver or kidney diseases to avoid the accumulation of nitrogen-containing substances in the body.

The use of acetylcysteine, especially at the beginning of treatment, can cause liquefaction of bronchial secretions and increase their volume. If the patient is unable to cough up sputum effectively, postural drainage and bronchoaspiration are necessary.

Acetylcysteine ​​affects histamine metabolism, so long-term therapy should not be prescribed to patients with histamine intolerance, as this may lead to symptoms of intolerance (headache, vasomotor rhinitis, itching).

Mucolytics can cause bronchial obstruction in children under 2 years of age. Due to the physiological characteristics of the respiratory system in children of this age group, the ability to clear respiratory secretions is limited. Therefore, mucolytics should not be used in children under 2 years of age.

A slight sulfuric odor is not a sign of a change in the properties of the medicinal product, but is specific to the active substance.

Pregnancy

Clinical data on the use of acetylcysteine ​​in pregnant women are limited. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development.

Children

Use for children over 12 years of age.

Drivers

There is no evidence that acetylcysteine ​​affects the ability to drive and use other mechanisms.

There are no data on cases of overdose with oral administration of acetylcysteine.

• From the side of the organs of hearing and vestibular apparatus: infrequently – tinnitus.
• Respiratory, thoracic and mediastinal disorders: rarely – dyspnoea, bronchospasm (mainly in patients with bronchial hyperreactivity associated with bronchial asthma); frequency unknown – rhinorrhea.
• Gastrointestinal: infrequently – vomiting, diarrhea, stomatitis, abdominal pain, nausea, heartburn; rarely – dyspepsia; frequency unknown – bad breath.
• From the nervous system: infrequently – headache.
• Cardiac disorders: infrequently – tachycardia, arterial hypotension.
• Vascular disorders: rare – hemorrhages.
• Blood and lymphatic system disorders: frequency unknown – anemia; cases of bleeding have been reported during the use of acetylcysteine, sometimes due to hypersensitivity reactions.
• Immune system disorders: uncommon – hypersensitivity; rare – anaphylactic shock, anaphylactic/anaphylactoid reactions.
• Skin and subcutaneous tissue disorders: infrequently – urticaria, rash, angioedema, itching; frequency unknown – exanthema, eczema, angioedema.
• General disorders and administration site conditions: uncommon – hyperthermia; frequency unknown – facial edema.

In very rare cases, there have been reports of individual severe skin reactions (Stevens-Johnson syndrome and Lyell’s syndrome) in association with acetylcysteine. In most cases, at least one other drug is more likely to be the cause of the mucocutaneous syndrome. Therefore, if any new changes appear on the skin or mucous membranes, you should consult a doctor and immediately discontinue acetylcysteine.

The use of antitussives with acetylcysteine ​​may increase sputum congestion due to a decrease in the cough reflex.

Activated charcoal reduces the effectiveness of acetylcysteine.

Acetylcysteine ​​is pharmacologically incompatible with antibiotics and proteolytic enzymes. When used simultaneously with antibiotics such as tetracyclines (except doxycycline), ampicillin, amphotericin B, cephalosporins, aminoglycosides, their interaction with the thiol group of acetylcysteine ​​is possible, which leads to a decrease in the activity of both drugs. Therefore, the interval between the use of these drugs should be at least 2 hours. This does not apply to cefixime and loracarbef.

Store in the original packaging, in a tightly closed tube, at a temperature not exceeding 25 ° C. Keep out of the reach of children.

Shelf life – 3 years.